KRAS and familial pancreatic carcinoma: Conversely, RNAi therapy targeting KRAS in combination with chemotherapy showed efficacy in treating locally advanced pancreatic cancer patients [40], whereas the G-protein-coupled receptor family C, member 5, group A gene was upregulated in PaCa cells, which led to enhanced drug resistance in PaCa cells [50].